Hong Kong Stock Movement: LONGBIO-B fell 10.18%, excess allocation triggered dilution concerns

Hong Kong Stock Movement

LONGBIO-B fell 10.18%. Based on recent key news:

1. On July 6, LONGBIO-B issued and allocated 2.12895 million H shares due to the full exercise of the over-allotment option, leading to a decline in stock price. Zhitong Finance reported that this event raised market concerns about the company's equity dilution, which in turn affected stock performance. The Hong Kong stock market has recently seen increased volatility, which needs attention.

Stocks with High Trading Volume in the Industry

Kelong Botai Bio fell 7.32%. Based on recent key news:

1. On July 8, Kelong Botai Bio announced the placement of 5.838 million new H shares at a placement price of HKD 470.2 per share, representing a discount of approximately 8.52% compared to the previous closing price. This move led to a decline in stock price, as the market reacted negatively to equity dilution and the extent of the discount. Source: Caihua News

2. On July 8, the company plans to use the proceeds from the placement for product research and development, clinical trials, and commercialization, with approximately 80% allocated for R&D, 15% for enhancing technical capabilities, and 5% for replenishing working capital. The market's enthusiasm for the use of funds did not offset the impact of the discount. Source: Zhitong Finance

3. On July 8, the shareholding ratio of Kelong Botai Bio's controlling shareholder will be diluted from approximately 64.10% to about 62.53% due to the placement, raising investor concerns about the dilution of shareholder rights. Source: Economic News Agency. The biotechnology industry has recently experienced significant fluctuations, which need attention.

Kangfang Bio fell 1.48%. Based on recent key news:

1. On July 7, Kangfang Bio recorded a cross-trade transaction of 202,000 shares, with each share priced 1.9% lower than the previous day's closing price, leading to a 2.6% decline in stock price. The transaction amount reached HKD 602 million, with a net active sell of HKD 42.96 million. Source: Economic News Agency

2. On July 6, the market is filled with anticipation for the upcoming ESMO and WCLC conferences, with domestic innovative drugs expected to become a global focus. Kangfang Bio is recommended as a mid-term investment target, as its participation logic in the global market remains intact. Source: Economic News Agency

3. On July 7, Kangfang Bio, as the only company globally with two tumor immunotherapy dual-antibody drugs on the market, is conducting multiple Phase III clinical studies, demonstrating its leading position in the innovative drug field. Source: Nandu Research. The performance of the innovative drug industry chain is improving, and demand is recovering.

Innovent Biologics fell 1.43%. Based on recent news:

1. On July 6, the overall Hong Kong stock market was performing well, and stocks like Innovent Biologics were in demand, with stock prices rising by 2% to 3%. However, market volatility led to a final decline of 1.43% for Innovent Biologics. Source: Zhitong Finance

2. On July 7, Innovent Biologics announced the placement and issuance of 1.882 million new shares, which diluted the stock price, leading to a decline. Source: Zhitong Finance

3. On July 7, Innovent Biologics reported the issuance of new shares, with the stock price rising by 0.11% from HKD 41.52 per share, but the overall market response was poor, leading to a price drop. Source: Zhitong Finance. The overall Hong Kong stock market is performing well, and pharmaceutical stocks are in demand Stocks Ranked Among the Top by Market Capitalization in the Industry

BeiGene fell by 1.52%. Based on recent key news:

1. On July 6, former BeiGene executive Liu Jian joined Guangzhou Pharmaceutical Group, raising market concerns about changes in the company's management, which affected the stock price.

2. On July 6, BeiGene announced that it needed to pay back taxes and late fees totaling approximately 446 million yuan. This tax adjustment had a significant impact on the company's profits, leading to a decline in the stock price.

3. On July 6, Hong Kong pharmaceutical stocks generally rose, but BeiGene failed to follow the market's upward trend due to the aforementioned events. The tax regulation in the pharmaceutical industry is tightening, increasing risks